Blood-brain barrier in drug discovery : optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs /

"Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Άλλοι συγγραφείς: Di, Li (Επιμελητής έκδοσης), Kerns, Edward Harvel (Επιμελητής έκδοσης)
Μορφή: Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Hoboken, New Jersey : Wiley, [2015]
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 07000nam a2200757 4500
001 ocn893389733
003 OCoLC
005 20170124071141.9
006 m o d
007 cr |||||||||||
008 141017t20152015nju ob 001 0 eng
010 |a  2014041569 
040 |a DLC  |b eng  |e rda  |e pn  |c DLC  |d N$T  |d DG1  |d YDXCP  |d E7B  |d UWO  |d COO  |d CDX  |d OCLCQ  |d OCLCO  |d MMU  |d DEBBG  |d LOA  |d KSU  |d GrThAP 
019 |a 904539318  |a 960204304 
020 |a 9781118788493  |q (ePub) 
020 |a 1118788494  |q (ePub) 
020 |a 9781118788547  |q (Adobe PDF) 
020 |a 1118788540  |q (Adobe PDF) 
020 |a 9781118788523  |q (ebook) 
020 |a 1118788524  |q (ebook) 
020 |a 9781322572406  |q (ebook) 
020 |a 1322572402  |q (ebook) 
020 |z 9781118788356  |q (hardback) 
020 |z 1118788354  |q (hardback) 
029 1 |a CHDSB  |b 006372535 
029 1 |a CHVBK  |b 333017153 
029 1 |a DEBBG  |b BV042795864 
029 1 |a GBVCP  |b 819918776 
029 1 |a DEBBG  |b BV043397214 
035 |a (OCoLC)893389733  |z (OCoLC)904539318  |z (OCoLC)960204304 
037 |a 688522  |b MIL 
042 |a pcc 
050 0 0 |a RM315 
060 1 0 |a WL 200 
072 7 |a MED  |x 071000  |2 bisacsh 
082 0 0 |a 615.7/8  |2 23 
049 |a MAIN 
245 0 0 |a Blood-brain barrier in drug discovery :  |b optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs /  |c edited by Li Di, Edward H. Kerns. 
246 3 0 |a Optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs 
264 1 |a Hoboken, New Jersey :  |b Wiley,  |c [2015] 
264 4 |c ©2015 
300 |a 1 online resource (xiv, 586 pages, 4 unnumbered pages of plates) :  |b illustrations (some color) 
336 |a text  |b txt  |2 rdacontent 
336 |a still image  |b sti  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
504 |a Includes bibliographical references and index. 
520 |a "Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher. 
588 |a Description based on online resource; title from PDF title page (ebrary, viewed May 9, 2016). 
505 0 |a Introduction and overview / Li Di, and Edward H. Kerns -- Part 1: Pharmacokinetics of brain exposure. Pharmacokinetics of CNS penetration / Andreas Reichel -- Free drug hypothesis for CNS drug candidates / Xingrong Liu and Cuiping Chen -- Species differences and impact of disease state on BBB / Jean-Marie Nicolas -- Part 2: Mechanisms of drugs across the blood-brain barrier. Passive diffusion permeability of the BBB: examples and SAR / Scott Summerfield, Phil Jeffrey, Jasminder Sahi, and Liangfu Chen -- Efflux transport at the BBB: examples and SAR / Jerome Hochman -- Establishment of P-glycoprotein structure-transport relationships to optimize CNS exposure in drug discovery / Jerome H. Hochman, Sookhee N. Ha, and Robert P. Sheridan -- Uptake transport at the BBB: examples and SAR / Ziquiang Cheng and Qian Liu -- Transport of protein and antibody therapeutics across the blood-brain barrier / William M. Pardridge -- Part 3: Predicting and measuring brain exposure of drugs. In silico tools for assessing brain exposure / Hongming Chen, Susanne Winiwarter, and Ola Engkvist -- In vitro assays for assessing BBB permeability: vascular cells, artificial membranes, brain slice, cell uptake / Alex Avdeef, Mária A. Deli, and Winfried Neuhaus -- Human-based in vitro endothelial cell models / Hannah K. Wilson and Eric Shusta -- Methods for assessing brain binding / Li Di and Cheng Chang -- In vivo studies of brain exposure in drug discovery / Edward H. Kerns -- PBPK modelling approach for predictions of human CNS drug brain distribution / Elizabeth C.M. de Lange -- PK/PD modeling of CNS drug candidates / Johan Gabrielsson, Stephan Hjorth, and Lambertus A. Peletier -- Microdialysis to assess free drug concentration in brain / William Kielbasa and Robert E. Stratford, Jr. -- Imaging techniques for central nervous system (CNS) drug discovery / Lei Zhang and Anabella Villalobos -- Part 4: Modulating brain penetration of leads during drug discovery. Designing CNS drugs for optimal brain exposure / Zoran Rankovic -- Case studies of CNS drug optimization: medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts -- Designing peripheral drugs for minimal brain exposure / Peter Bungay, Sharan Bagal, and Andy Pike -- Case studies of non-CNS drugs to minimize brain penetration: nonsedative antihistamines / Andrew Crowe -- Part 5: Case studies in CNS drug discovery. Case study 1: the discovery and development of perampanel / Antonio Laurenza, Jim Ferry, Haichen Yang, Shigeki Hibi, Takahisa Hanada, and Andrew Satlin -- Case study 2: the discovery and development of the multimodal acting antidepressant vortioxetine / Christoffer Bundgaard, Alan L. Pehrson, Connie Sánchez, and Benny Bang-Andersen -- Part 6: Drug delivery techniques to CNS. Brain delivery using nanotechnology / Huile Gao and Xinguo Jiang -- Intranasal delivery to the central nervous system / Lisbeth Illum -- Part 7: Future prospects in blood-brain barrier understanding and drug discovery. Future perspectives / N. Joan Abbott . 
650 0 |a Blood-brain barrier  |x Metabolism. 
650 0 |a Drug development. 
650 7 |a MEDICAL  |x Pharmacology.  |2 bisacsh 
650 1 2 |a Blood-Brain Barrier  |x metabolism. 
650 1 2 |a Central Nervous System Agents  |x pharmacokinetics. 
650 2 2 |a Blood-Brain Barrier  |x drug effects. 
650 2 2 |a Central Nervous System Diseases  |x drug therapy. 
650 2 2 |a Drug Discovery  |x methods. 
650 2 2 |a Drug-Related Side Effects and Adverse Reactions  |x prevention & control. 
655 4 |a Electronic books. 
655 0 |a Electronic books. 
700 1 |a Di, Li,  |e editor. 
700 1 |a Kerns, Edward Harvel,  |e editor. 
776 0 8 |i Print version:  |t Blood-brain barrier in drug discovery.  |d Hoboken, New Jersey : John Wiley & Sons Inc., [2015]  |z 9781118788356  |w (DLC) 2014040935  |w (OCoLC)889736023 
856 4 0 |u https://doi.org/10.1002/9781118788523  |z Full Text via HEAL-Link 
994 |a 92  |b DG1